Sermorelin

Sermorelin is a truncated analog of human growth hormone-releasing hormone (GHRH), containing the first 29 amino acids of the naturally occurring 44-amino acid GHRH molecule. This shortened sequence retains full biological activity, meaning it can effectively stimulate the pituitary gland to synthesize and secrete growth hormone. Originally developed by Serono Laboratories and FDA-approved in 1997 under the brand name Geref, Sermorelin was initially used as a diagnostic agent for growth hormone deficiency and later approved for therapeutic use in children with growth failure. Unlike exogenous growth hormone administration, sermorelin works by stimulating the body's own GH production pathways, which maintains normal physiological feedback mechanisms and pulsatile release patterns. This approach is considered more physiologically natural than direct GH replacement, as the pituitary gland regulates output based on the body's needs.